In DepthCOVID-19

Dosing debates, transparency issues roil vaccine rollouts

See allHide authors and affiliations

Science  08 Jan 2021:
Vol. 371, Issue 6525, pp. 109-110
DOI: 10.1126/science.371.6525.109


Last-minute vaccine dosing changes that could gamble away proven COVID-19 protection and undermine public trust. Controversial approvals without any efficacy data. Vaccinemakers at odds with countries hosting their clinical trials. The COVID-19 vaccine landscape keeps changing almost daily, simultaneously raising hopes and triggering confusion and scientific debates. Over the past few weeks, COVID-19 vaccines developed in the United Kingdom, China, and India moved toward widespread rollout, offering new weapons in the face of a fast-spreading viral variant that threatens to deepen the crisis. But many came with controversies, and U.K. regulators sparked a debate when they endorsed a sharp departure from the expected dosing schedule for a newly authorized vaccine from AstraZeneca and the University of Oxford and one from Pfizer and BioNTech.

View Full Text

Stay Connected to Science